Histologically or cytologically confirmed adenocarcinoma with locally advanced, unresectable, or metastatic disease

No prior systemic treatment for metastatic disease

Adjuvant therapy ≥6 months prior to study entry with no residual toxic effects

Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3

Life expectancy ≥12 weeks

Adequate hematologic, hepatic, and renal function

Negative pregnancy test within 72 hours of study drug and use of effective contraception among women of childbearing potential

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer